{"name":"Akesobio","slug":"akesobio","ticker":"","exchange":"","domain":"akesobio.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AK-104","genericName":"AK-104","slug":"ak-104","indication":"Other","status":"phase_1"},{"name":"AK-105","genericName":"AK-105","slug":"ak-105","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"AK120","genericName":"AK120","slug":"ak120","indication":"Solid tumors (specific indication under clinical evaluation in Phase 3)","status":"phase_3"}]}],"pipeline":[{"name":"AK-104","genericName":"AK-104","slug":"ak-104","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AK-105","genericName":"AK-105","slug":"ak-105","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AK120","genericName":"AK120","slug":"ak120","phase":"phase_3","mechanism":"AK120 is an engineered T cell engager that redirects patient T cells to recognize and eliminate cancer cells expressing specific tumor antigens.","indications":["Solid tumors (specific indication under clinical evaluation in Phase 3)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":2,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}